ALVO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -4.62% compared to Alvotech's net margin of 21.47%. Alvotech's return on equity of -- beat Johnson & Johnson's return on equity of 33.27%.

Alvotech has a consensus price target of $25.60, signalling upside risk potential of 368.01%. On the other hand Johnson & Johnson has an analysts' consensus of $203.42 which suggests that it could grow by 0.74%. Given that Alvotech has higher upside potential than Johnson & Johnson, analysts believe Alvotech is more attractive than Johnson & Johnson.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.55% to investors and pays a quarterly dividend of $1.30 per share. Alvotech pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alvotech quarterly revenues are $113.7M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Alvotech's net income of -$5.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Alvotech's price-to-earnings ratio is 23.75x while Johnson & Johnson's PE ratio is 19.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 3.01x versus 5.31x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Procaps Group SA has a net margin of -4.62% compared to Alvotech's net margin of --. Alvotech's return on equity of -- beat Procaps Group SA's return on equity of --.

Alvotech has a consensus price target of $25.60, signalling upside risk potential of 368.01%. On the other hand Procaps Group SA has an analysts' consensus of -- which suggests that it could grow by 19820.32%. Given that Procaps Group SA has higher upside potential than Alvotech, analysts believe Procaps Group SA is more attractive than Alvotech.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Procaps Group SA has a beta of 61.716, suggesting its more volatile than the S&P 500 by 6071.584%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Procaps Group SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Procaps Group SA pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are larger than Procaps Group SA quarterly revenues of --. Alvotech's net income of -$5.3M is higher than Procaps Group SA's net income of --. Notably, Alvotech's price-to-earnings ratio is 23.75x while Procaps Group SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 3.01x versus 0.01x for Procaps Group SA. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -4.62% compared to Alvotech's net margin of 38.89%. Alvotech's return on equity of -- beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Alvotech has a consensus price target of $25.60, signalling upside risk potential of 368.01%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.74%. Given that Alvotech has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Alvotech is more attractive than Regeneron Pharmaceuticals, Inc..

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Alvotech pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Alvotech's net income of -$5.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Alvotech's price-to-earnings ratio is 23.75x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 3.01x versus 5.56x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics, Inc. has a net margin of -4.62% compared to Alvotech's net margin of -208.69%. Alvotech's return on equity of -- beat Voyager Therapeutics, Inc.'s return on equity of -46.39%.

Alvotech has a consensus price target of $25.60, signalling upside risk potential of 368.01%. On the other hand Voyager Therapeutics, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 250.47%. Given that Alvotech has higher upside potential than Voyager Therapeutics, Inc., analysts believe Alvotech is more attractive than Voyager Therapeutics, Inc..

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Voyager Therapeutics, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.615%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Voyager Therapeutics, Inc. pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are larger than Voyager Therapeutics, Inc. quarterly revenues of $13.4M. Alvotech's net income of -$5.3M is higher than Voyager Therapeutics, Inc.'s net income of -$27.9M. Notably, Alvotech's price-to-earnings ratio is 23.75x while Voyager Therapeutics, Inc.'s PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 3.01x versus 7.99x for Voyager Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.